Navigation Links
SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER FINANCIAL RESULTS
Date:11/12/2013

w a significant reduction of sodium in foods and beverages yet maintain the salty taste desirable to consumers.  This program is an important research focus for the Company's longer-term pipeline.
Senomyx is analyzing a proprietary database of proteins found in taste buds to determine the role of a number of proteins that may be relevant to salt taste perception.  The current focus is on targeted analytical approaches to identify specific proteins that could be viable candidates for the receptors or co-factors responsible for salt taste.  Taste bud proteins under investigation include potential lead candidates for the salt taste receptor, as well as proteins that may be involved in the process for signaling the sensory perception of saltiness.  

Intellectual Property:  Senomyx continues to be diligent in seeking protection for its intellectual property.  As of September 30, 2013, the Company is the owner or exclusive licensee of 396 issued patents and several hundred pending patent applications in the U.S., Europe, and elsewhere related to proprietary taste science technologies.  

Financial Review:At September 30, 2013, Senomyx held $35.6 million in cash, cash equivalents and investments available-for-sale.

Total revenues were $6.7 million for the quarter ended September 30, 2013, compared to $7.9 million for the quarter ended September 30, 2012.  Total revenues for the nine months ended September 30, 2013 were $21.9 million, compared to $23.1 million for the nine months ended September 30, 2012.

Development revenues were $5.9 million in the third quarter of 2013 and $7.0 million in the third quarter of 2012.  Development revenues were $18.1 million and $20.2 million for the nine months ended September 30, 2013 and 2012, respectively.  These changes are primarily due to one-time development milestones earned in 2012, including $1.3 million related to our Sweet Tas
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
3. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
5. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
6. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
7. SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER FINANCIAL RESULTS
8. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE MIDWEST IDEAS INVESTOR CONFERENCE
9. Senomyx Announces Management Update
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 The ... system (Nexera UC) can sequentially analyze up to ... combined with high-sensitivity detection of targets by mass ... designed to fulfill the measurement requirements of a ... food products, drug delivery and search for disease ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... for judgment notwithstanding the verdict, a new trial, and ...
(Date:2/26/2015)... LA JOLLA, Calif. , Feb. 26, 2015 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery and development ... Kleanthis G. Xanthopoulos , Ph.D., President and Chief Executive ... the Cowen and Company 35 th Annual Healthcare ... EST.  The conference is being held at the Boston ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... with YWCA & Roche to Educate Patients on, ... and a Career -, NEW YORK, March 10 ... Careers, a non-profit program,founded by Cosmetic Executive Women Foundation, ... the hundreds of thousands of people,living with cancer on ...
... J.D., joins BrainCells, Board of ... ... (BCI), a,biopharmaceutical company utilizing its platform technology to identify and,develop compounds ... nervous system (CNS) diseases, announced today that it has,completed a $30 ...
... CITY, Calif., March 10, Otsuka Pharmaceutical Co., Ltd. ... today announced the closing of the,previously announced transaction ... Busulfex(R) (busulfan), including trademarks, patents,intellectual property and related ... Busulfex is an oncologic product marketed and sold ...
Cached Biology Technology:First-Ever 'Cancer and Careers' Seminar Debuts in Orange County 2First-Ever 'Cancer and Careers' Seminar Debuts in Orange County 3BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 3Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 4
(Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... Antibiotic resistance is a growing human health concern. ... other pharmaceuticals to be present in surface waters ... underlying groundwater. In a recent article in the ... at Colorado State University (CSU) describe a study ...
... potential risks growing" If so, who or ... newswiresenvironmental and consumer organizations, scientists, law makers, or ... decide to cover a nanotechnology story, especially one ... correspondents face special challenges reporting on a technology ...
... Antarctica, Nov. 28, 2007 -- A second season in ... exceeded all expectations, according to the co-chief scientists of ... (Nov. 21), the drilling team passed the 1,000-meter mark ... in McMurdo Sound, and with a remarkable recovery rate ...
Cached Biology News:Manure management reduces levels of antibiotics and antibiotic resistance genes 2Nanotechnology and the media: The inside story 2ANDRILL's 2nd Antarctic drilling season exceeds all expectations 2ANDRILL's 2nd Antarctic drilling season exceeds all expectations 3
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
CBF-B (G-2)...
HSV-2 gD (0191)...
... Dynabeads Epoxy (4.5 m). Hydrophobic naked ... Ideal for coupling of antibodies for cell ... coupling with covalent binding of primary amine ... (SH)) occurring within 16-20 hours. Coupling reactions ...
Biology Products: